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whether, in patients not responding to standard doses of duloxetine or pregabalin, combining both med-
ications is superior to increasing each drug to its maximum recommended dose. For initial 8-week ther-
apy, either 60 mg/day duloxetine (groups 1, 2) or 300 mg/day pregabalin (groups 3, 4) was given.
Thereafter, in the 8-week combination/high-dose therapy period, only nonresponders received 120 mg/
day duloxetine (group 1), a combination of 60 mg/day duloxetine and 300 mg/day pregabalin (groups
2, 3), or 600 mg/day pregabalin (group 4). Primary outcome (Brief Pain Inventory Modiﬁed Short Form
[BPI-MSF] 24-hour average pain change after combination/high-dose therapy) was analyzed comparing
combination (groups 2, 3 pooled) with high-dose monotherapy (groups 1, 4 pooled). Secondary
end-points included response rates, BPI-MSF severity items, and comparison of duloxetine and pregabalin
in BPI-MSF average pain. Eight hundred four patients were evaluated for initial therapy and 339 for com-
bination/high-dose therapy. There were no signiﬁcant differences between combination and high-dose
monotherapy regarding BPI-MSF average pain (mean change: combination: 2.35; high-dose mono-
therapy: 2.16; P = 0.370) and most secondary end points, which, however, consistently favoured com-
bination therapy. Fifty-percent response rates were 52.1% for combination and 39.3% for high-dose
monotherapy (P = 0.068). In exploratory analyses of the initial 8-week therapy uncorrected for multiple
comparisons, 60 mg/day duloxetine was found superior to 300 mg/day pregabalin (P < 0.001). Both drugs
and their combination were well tolerated. Although not signiﬁcantly superior to high-dose mono-
therapy, combination therapy was considered to be effective, safe, and well tolerated.
Crown Copyright  2013 Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. All rights reserved.1. Introduction
Diabetic peripheral neuropathy is a common chronic complica-
tion present in up to 50% of all diabetic patients with a long disease
history [27]. Approximately 16%-26% of all patients with diabetes
are known to develop diabetic peripheral neuropathic pain
[7,30]. Diabetic peripheral neuropathic pain causes moderate to
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and has a major negative impact on sleep, mood, functionality,
and other aspects of quality of life [7,15,30]. Although traditionally,
the ﬁrst step in the management of diabetic peripheral neuropathic
pain has been to improve and stabilize glycemic control [27], addi-
tional drugs are usually required [28].
Clinical management of diabetic peripheral neuropathic pain is
challenging, and response to existing treatments is often inade-
quate [28]. While tricyclic antidepressants, duloxetine, venlafax-
ine, pregabalin, and gabapentin have been recommended for
ﬁrst-line use in painful diabetic neuropathy [2], there is only lim-
ited evidence of efﬁcacy for certain other anticonvulsants such as
lamotrigine, carbamazepine, oxcarbazepine, valproate, topiramate,
and lacosamide [9]. Among several disease-modifying agents, only
the intravenous alpha-lipoic acid is supported when using 600 mg
over a 3-week period [28]. However, duloxetine, a selective seroto-
nin and norepinephrine re-uptake inhibitor, and pregabalin, an
anticonvulsant that modulates the a2-d-calcium channel subunits
[2,9,11,12], are the only 2 drugs approved by both the US Food
and Drug Administration and the European Medicines Agency for
the treatment of neuropathic pain in diabetes [28]. However, when
given as monotherapy at standard doses (60 and 300 mg/day,
respectively), it has been shown that both drugs provide substan-
tial clinical pain relief in only about 40% of patients [21,23,25].
In patients showing partial response to standard therapy with
either drug, combination treatment of duloxetine and pregabalin
at standard doses may provide better pain relief and tolerability
than the administration of maximum doses of each drug, which
may be limited by adverse effects [10]. Due to the different but
potentially complementary mechanisms of action of duloxetine
and pregabalin [8,18], their combination may have a clinically
additive effect in the treatment of painful diabetic neuropathy,
resulting in an enhanced pain relief compared to the use of either
drug alone. However, there have been no clinical studies exploring
this hypothesis.
The COMBO-DN (COmbination vs. Monotherapy of pregaBalin
and dulOxetine in Diabetic Neuropathy) study was designed to
address this common clinical question: ‘‘Is it better to increase
the dose of the current ﬁrst-line recommended monotherapy or
to combine with another ﬁrst-line recommended drug early on
in patients with insufﬁcient pain relief?’’ We compared the efﬁ-
cacy and tolerability of a ﬁxed combination of standard recom-
mended doses of duloxetine (60 mg/day) plus pregabalin
(300 mg/day) with maximal doses of either drug given as mono-
therapy, that is, duloxetine 120 mg/day or pregabalin 600 mg/
day, in patients with diabetic peripheral neuropathic pain not
responding to the standard recommended dose of either drug
[6,19]. In exploratory analyses uncorrected for multiple compari-
sons, the study also provided the opportunity to directly compare
duloxetine (60 mg/day) with pregabalin (300 mg/day) for initial
pain therapy over 8 weeks.2. Methods
2.1. Study design and population
This was a multinational, randomized, double-blind, parallel-
group study in patients with diabetic peripheral neuropathic pain
conducted in Europe (Croatia, France, Germany, Greece, Italy, Po-
land, Spain, Sweden, The Netherlands, Turkey, and United King-
dom), Australia, Canada, Mexico, and South Korea, from February
2010 until November 2011. The study was approved by applicable
Ethical Review Boards and followed applicable laws and regula-
tions, Good Clinical Practice (according to International Conference
on Harmonisation), and the Declaration of Helsinki. The EudraCTtrial number is 2009-010063-16 and ClinicalTrials.gov identiﬁer
is NCT01089556.
The study includedmale or female outpatientsP18 years of age,
who were either not receiving any medication for diabetic periph-
eral neuropathic pain or who completed a 2-week washout period,
and who had never received any duloxetine or pregabalin, except
for a <15-day course of duloxetine or pregabalin treatment. Patients
had to have pain due to bilateral peripheral neuropathy caused by
type 1 or type 2 diabetes mellitus, beginning in the feet in a rela-
tively symmetrical fashion. Daily pain should have been present
for at least 3 months and the diagnosis had to be conﬁrmed by a
score of P3 on the Michigan Neuropathy Screening Instrument at
screening [20]. Furthermore, patients had to present with a 24-hour
average pain severity of P4 on the Brief Pain Inventory Modiﬁed
Short Form (BPI-MSF) [5], and stable glycemic control with haemo-
globin A1c (HbA1c) 6 12%. Exclusion criteria included any suicidal
risk as judged by the investigator or as deﬁned by a score of P2
on item 9 of the Beck Depression Inventory II (BDI-II) [3]. Investiga-
tors were neurologists, diabetologists, and pain specialists.
The study consisted of 4 study periods (Fig. 1): a 2-week screen-
ing and washout period, an 8-week initial therapy period, an 8-
week combination/high-dose therapy period, and a 2-week taper
period. After screening, eligible patients were randomized and
started treatment at visit 2. Treatment regimens during the initial
and the combination/high-dose therapy periods were as shown in
Fig. 1. At the start of the combination/high-dose therapy period,
treatment response was assessed based on the change in the BPI-
MSF 24-hour average pain score during the initial therapy period.
Patients with P30% improvement in pain were considered
‘‘responders’’ and were discontinued, while nonresponders (pa-
tients with <30% improvement) received double-blind treatment
for another 8 weeks, starting at visit 5 (baseline for the combina-
tion/high-dose therapy period). During the concluding recom-
mended taper period, study drug doses were tapered down
(Fig. 1). Doses were also tapered down for patients discontinuing
earlier.
In case of signiﬁcant intolerability at the target dose level, based
on investigator and patient decision, the dose was reduced for 1
week and then increased back to the planned dose level. Patients
still not tolerating the planned dose were discontinued.
2.2. Randomization and blinding
At the start of the initial therapy period, patients were random-
ized in a 1:1:1:1 ratio to 4 parallel groups stratiﬁed by site, based
on a computer-generated sequence using a centralized interactive
voice response system. Blinding was maintained throughout all
treatment periods by using over-encapsulated duloxetine and pre-
gabalin capsules, matching placebo, and an identical dosing regi-
men for all groups in terms of timing and number of capsules.
2.3. Study outcome measures
The self-reported BPI-MSFmeasures the severity of pain and the
interference of pain with function [5]; it was assessed at clinical
visits without using patient diaries. The primary outcome measure
was the BPI-MSF 24-hour average pain score. Patients rated their
average pain severity over the previous 24 hours on an 11-point
scale ranging from 0 (no pain) to 10 (pain as bad as you can imag-
ine). Response rates were evaluated based on a 30%, 50%, or 2-point
reduction in BPI-MSF 24-hour average pain.
Secondary outcome measures included other BPI-MSF items,
the Clinical Global Impression of Improvement scores, the Patient
Global Impression of Improvement scores [16], the Neuropathic
Pain Symptom Inventory (NPSI) questionnaire total score, and its
5 subscores (burning spontaneous pain, pressing spontaneous
Fig. 1. Study design. DLX, duloxetine; PGB, pregabalin.
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sias) [4], and the total and anxiety and depression subscale scores
of the Hospital Anxiety and Depression Scale (HADS) [32]. Another
important secondary measure was the change in BPI-MSF 24-hour
average pain during initial therapy period, comparing standard
doses of duloxetine and pregabalin, that is, 60 mg/day of duloxe-
tine and 300 mg/day of pregabalin, corresponding to half the max-
imum doses for each drug.
Safety assessments included frequencies of treatment-emer-
gent adverse events (TEAEs) and serious adverse events (SAEs, de-
ﬁned as any event resulting in prolonging hospitalization or death,
life-threatening experience, severe or permanent disability), vital
signs, body weight, standard clinical laboratory tests (including
fasting blood glucose and HbA1c), and the BDI-II questionnaire to
assess the severity of depression and any suicidal risks with its
item 9 [3].
2.4. Statistical analysis
The study was powered to detect a difference of 1 point on the
BPI-MSF 24-hour average pain item score at the end of the study
between the combination arm (pooled groups 2 and 3) and the
monotherapy arm (pooled groups 1 and 4) with a 2-sided test
and 90% power, assuming an SD of 2.5. This analysis required
135 patients per therapy group (nQuery Advisor 7.0; Statistical
Solutions, Saugus, MA, USA). Assuming 60% of patients responding
to initial therapy and 15% discontinuing during initial therapy, a
total of 800 patients were planned to be randomized.
Analyses were conducted according to intention-to-treat princi-
ples. Patients were included in efﬁcacy analyses if they were trea-
ted and had a baseline and at least one postbaseline assessment of
any efﬁcacy parameter during the combination/high-dose therapy
period (efﬁcacy population). The safety population included all
randomised and treated patients. Visit 2 was baseline for the initial
and visit 5 for the combination/high-dose therapy period.
Mixed-model repeated-measures (MMRM) analysis was used to
compare combination and high-dose monotherapy by modelling
the change from baseline (start of combination/high-dose therapy)
to end of combination/high-dose therapy in the BPI-MSF 24-hour
average pain score.The model included terms for treatment (combination/mono-
therapy), site, visit, treatment-by-visit interaction, initial therapy
(duloxetine/pregabalin), baseline score, and baseline-by-visit
interaction. An unstructured covariance structure was assumed.
Means and their 95% conﬁdence intervals (CIs) were presented
for each therapy group and for between-therapy differences, to-
gether with associated P-values.
Secondary efﬁcacy analyses were exploratory and included
MMRM to compare the respective treatment groups within each
treatment period. Response rates were compared between treat-
ments using a Cochran-Mantel-Haenszel test stratiﬁed by site. All
tests were prespeciﬁed. No adjustment for multiplicity was made.
Safety measures were descriptively summarized. Frequencies of
patients with TEAEs and patients with an increase in the score for
BDI-II item 9 were compared between treatments using Fisher’s
exact test.
Data were analyzed using SAS software version 8.2 or higher
(SAS Institute Inc, Cary, NC, USA).
2.5. Role of the funding source
The sponsor, Eli Lilly & Company (Indianapolis, IN, USA), was in-
volved in study design, in the collection, analysis, and interpreta-
tion of data, in the writing of the manuscript, and in the decision
to submit the paper for publication.
3. Results
3.1. Patient disposition and baseline characteristics
Of 1074 patients screened, 804 were randomized and received
initial therapy with duloxetine 60 mg/day (n = 401) or pregabalin
300 mg/day (n = 403) (Fig. 2). After 8 weeks of treatment, 164 pa-
tients (40.9%) treated with duloxetine and 116 (28.8%) treated with
pregabalin discontinued the study because they showed P30%
improvement in BPI-MSF 24-hour average pain. Of the 343 patients
who continued treatment in the combination/high-dose therapy
period, 170 received combination therapy and 173 high-dose
monotherapy, according to the sequences the patients had been
randomized to. Discontinuation reasons other than achieving
Fig. 2. Patient disposition ﬂow chart. DLX, duloxetine; PGB, pregabalin; V5, visit 5. aIncludes 7 patients (4 patients of group 1, 3 of group 2) who were responders at the end of
initial therapy. bIncludes 5 patients (4 patients of group 3, 1 of group 4) who were responders at the end of initial therapy.
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between treatment groups in both treatment periods (Fig. 2).
The efﬁcacy population for the combination/high-dose therapy
period included 169 patients in the combination therapy group
and 170 in the high-dose monotherapy group.
Patient characteristics (Table 1) as well as neuropathic pain efﬁ-
cacy measures and mood assessments (Table 2) at baseline of the
initial therapy period were similar to those at baseline (i.e., visit
5) of the combination/high-dose therapy period.
3.2. Efﬁcacy
3.2.1. Combination/high-dose therapy period
At the end of the combination/high-dose therapy period, no sta-
tistically signiﬁcant difference between combination and high-
dose monotherapy in the primary variable of the mean change in
BPI-MSF 24-hour average pain was seen (MMRM: combination:
2.35; high-dose monotherapy: 2.16; mean difference: 0.19;
95% CI 0.61-0.23; P = 0.370; Fig. 3). The corresponding mean
(SD) percent change was 39.4% (33.62%) with combination ther-
apy, and 34.3% (37.89%) with high-dose monotherapy. Similarly,
a numerically but nonsigniﬁcantly larger proportion of patients in
the combination group (n = 86 [52.1%]) compared to the high-dose
monotherapy group (n = 64 [39.3%]) achieved P50% reduction in
BPI-MSF 24-hour average pain at the end of combination/high-
dose therapy (P = 0.068; Table 3). Within the high-dose mono-
therapy group, 46.9% of patients treated with 600 mg/day pregab-
alin experienced a pain reduction of P50% compared to 28.4%
treated with 120 mg/day duloxetine (Table 3).
At the end of the combination/high-dose therapy period, be-
tween-therapy differences for other secondary efﬁcacy measures
consistently favoured combination therapy (Fig. 4B); however, dif-ferences were not statistically signiﬁcant, with the exception of the
HADS anxiety subscale (MMRM: mean difference: 0.62 [0.31];
95% CI 1.228, 0.002; P = 0.049).
3.2.2. Initial therapy period
In exploratory analyses uncorrected for multiple comparisons
of the initial therapy period, statistically signiﬁcant differences in
average pain relief as measured by the mean change in BPI-MSF
24-hour average pain were seen in favour of duloxetine compared
to pregabalin at 4 weeks (MMRM: duloxetine: 1.76; pregabalin:
1.40; mean difference: 0.37; 95% CI 0.63, 0.10; P = 0.007)
and at 8 weeks (MMRM: duloxetine: 2.30; pregabalin: 1.68;
mean difference: 0.61; 95% CI 0.90, 0.33; P < 0.001) (Fig. 3A).
After initial therapy, a higher proportion of patients in the duloxe-
tine group (n = 151 [40.3%]) achieved P50% reduction in BPI-MSF
24-hour average pain compared to the pregabalin group (n = 104
[27.8%]; P < 0.001; Table 3). Superior results in favour of duloxetine
were also seen for all BPI-MSF subscores, all NPSI scores with the
exception of evoked pains, and all HADS scores (Fig. 4A). Mean
changes in NPSI total score were 19.44 for duloxetine and
14.68 for pregabalin (MMRM: mean difference: 4.76; 95% CI
7.35, 2.16; P < 0.001), and in HADS total score 3.07 and
2.06 (MMRM: mean difference: 1.01; 95% CI 1.70, 0.32;
P = 0.004), respectively.
3.3. Safety
TEAE frequencies were generally higher during initial therapy
than during combination/high-dose therapy. Within each period,
no statistically signiﬁcant differences were seen between treat-
ment groups for TEAE categories as displayed in Table 4. In the ini-
tial therapy period, most common TEAEs (>10% of all patients)
Table 1
Baseline characteristics.
Initial therapy Combination/high-dose therapy
Duloxetine Pregabalin Combination therapy High-dose
monotherapy
N Statistic N Statistic N Statistic N Statistic
Age (years), mean (SD) 401 61.5 (10.62) 403 61.9 (10.95) 169 61.0 (9.78) 170 61.2 (10.46)
P65 years, n (%) 156 (38.9) 157 (39.0) 61 (36.1) 63 (37.1)
Male, n (%) 401 219 (54.6) 403 229 (56.8) 169 89 (52.7) 170 92 (54.1)
Race, n (%) 398 400 167 169
White 324 (81.4) 328 (82.0) 140 (83.8) 146 (86.4)
American Indian or Alaska Native 37 (9.3) 36 (9.0) 8 (4.8) 8 (4.7)
Asian 34 (8.5) 34 (8.5) 19 (11.4) 14 (8.3)
Other 3 (0.8) 2 (0.5) 0 1 (0.6)
Weight (kg), mean (SD) 400 85.3 (19.43) 403 86.5 (19.58) 169 85.0 (19.27) 170 87.7 (18.92)
Body mass index (kg/m2), mean (SD) 399 30.7 (6.18) 403 30.9 (5.94) 169 30.5 (6.03) 170 31.4 (6.12)
Current alcohol consumption, n (%) 401 111 (27.7) 403 119 (29.5) 169 45 (26.6) 170 45 (26.5)
Time since diabetic diagnosis onset (years), median (Q1, Q3) 401 11 (6.5, 18.0) 403 11 (5.8, 18.8) 169 11 (4.9, 17.6) 170 11 (5.9, 20.0)
HbA1c (%), mean (SD) 401 8.0 (1.70) 401 7.9 (1.57) 166 7.6 (1.69) 166 7.7 (1.56)
Time since neuropathy diagnosis onset (years), median (Q1, Q3) 401 2 (0.9, 5.2) 403 2 (0.8, 4.8) 169 2 (1.0, 5.2) 170 2 (0.8, 5.3)
Time since neuropathic pain onset (years), median (Q1, Q3) 401 2 (0.8, 4.7) 403 2 (0.7, 3.8) 169 2 (0.6, 3.8) 170 1 (0.6, 4.0)
Received no prior DPNP therapy, n (%) 401 263 (65.6) 403 267 (66.3) 169 99 (58.6) 170 115 (67.6)
Concomitant diseases reported by P10% of patients at baseline, n (%) 401 403 NA NA
Any concomitant disease 359 (89.5) 356 (88.3) NA NA
Hypertension 261 (65.1) 262 (65.0) NA NA
Hyperlipidemia 70 (17.5) 82 (20.3) NA NA
Hypercholesterolemia 50 (12.5) 62 (15.4) NA NA
Dyslipidemia 52 (13.0) 38 (9.4) NA NA
Osteoarthritis 45 (11.2) 43 (10.7) NA NA
DPNP, diabetic peripheral neuropathic pain; HbA1c, hemoglobin A1c; N, total number of patients with available data; n, number of patients with characteristic; NA, not
applicable; Q1, ﬁrst quartile; Q3, third quartile.
Table 2
Efﬁcacy measures at baseline.
Efﬁcacy measure Initial therapya Combination/high-dose therapyb
Duloxetine Pregabalin Combination therapy High-dose monotherapy
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Brief Pain Inventory (BPI)
Average pain 401 6.0 (1.55) 401 6.0 (1.57) 169 5.4 (1.39) 170 5.4 (1.51)
Pain at its worst 401 7.2 (1.66) 403 7.1 (1.70) 169 6.0 (1.75) 170 6.2 (1.77)
Pain at its least 401 4.5 (2.17) 403 4.4 (2.09) 169 4.1 (1.88) 170 3.9 (1.98)
Pain right now 401 5.2 (2.22) 403 5.2 (2.24) 169 4.5 (2.07) 170 4.5 (2.28)
Total interference score 399 4.9 (2.05) 401 4.9 (2.14) 168 4.1 (1.96) 170 4.1 (2.16)
General activity 401 5.4 (2.54) 402 5.5 (2.40) 169 4.4 (2.22) 170 4.5 (2.36)
Mood 401 4.9 (2.52) 402 4.7 (2.55) 169 4.1 (2.27) 170 4.4 (2.42)
Walking ability 401 5.5 (2.58) 402 5.5 (2.55) 169 4.6 (2.37) 170 4.5 (2.43)
Normal work 399 5.2 (2.50) 401 5.0 (2.40) 168 4.3 (2.20) 170 4.2 (2.36)
Relations with other people 401 3.7 (2.57) 402 3.7 (2.62) 169 3.4 (2.34) 170 3.3 (2.50)
Sleep 401 5.4 (2.76) 402 5.6 (2.81) 169 4.2 (2.53) 170 4.2 (2.59)
Enjoyment of life 401 4.4 (2.81) 402 4.4 (2.82) 169 3.6 (2.38) 170 3.7 (2.63)
Neuropathic Pain Symptom Inventory (NPSI)c
Total score 399 47.3 (19.16) 397 47.7 (20.46) 169 39.4 (17.96) 170 39.4 (19.91)
Hospital Anxiety and Depression Scale (HADS)d
Total score 397 12.3 (7.85) 399 12.0 (7.60) 168 10.8 (7.41) 169 9.8 (7.67)
Anxiety subscale score 398 6.8 (4.31) 400 6.6 (4.32) 169 5.7 (4.04) 169 5.1 (4.25)
Depression subscale score 399 5.5 (4.19) 402 5.5 (3.88) 168 5.1 (3.94) 170 4.8 (3.87)
N, Number of evaluable patients with available data.
a Baseline refers to visit 2, before start of any study drug.
b Baseline refers to visit 5, before start of intensive treatment combination/high-dose therapy (combination therapy or high-dose monotherapy with increased dose).
c The NPSI total score ranges from 0 (no pain) to 100 (worst pain).
d The HADS total score ranges from 0 (best) to 42 (worst), with each of the subscale scores ranging from 0 (best) to 21 (worst).
2620 S. Tesfaye et al. / PAIN

154 (2013) 2616–2625were dizziness (7.2% [duloxetine] vs. 15.1% [pregabalin]; P < 0.001),
somnolence (10.0% [duloxetine] vs. 10.9% [pregabalin]; P = 0.730),
and nausea (14.2% [duloxetine] vs. 6.5% [pregabalin]; P < 0.001).
During the combination/high-dose therapy period, none of the
TEAEs were reported by more than 3% of patients (Table 5), and dif-
ferences between therapies were not statistically signiﬁcant. A to-
tal of 38 patients, 25 (3.1%) during initial therapy and 13 (3.8%)during combination/high-dose therapy, experienced SAEs, and
none of the SAEs occurred in more than 3 patients (60.7%) of any
therapy group. No relevant differences were seen between thera-
pies in either period. During the initial therapy period, the only
SAEs occurring in more than 2 patients in either treatment group
were chest pain, hyperglycemia, and suicidal ideation. During com-
bination/high-dose therapy, the only SAE experienced by more
Fig. 3. Brief Pain Inventory Modiﬁed Short Form 24-hour average pain item score over time – initial therapy (A) and combination/high-dose therapy (B) period. BPI, Brief Pain
Inventory; CI, conﬁdence interval; DLX, duloxetine; LS, least squares; PGB, pregabalin. ⁄Statistically signiﬁcant. Note: P-values from a mixed-model repeated-measures
analysis including terms for treatment (duloxetine/pregabalin or combination/high-dose monotherapy, respectively), site, visit, treatment-by-visit interaction, baseline score
(from visit 2 or visit 5, respectively, and baseline-by-visit interaction. The model for the combination/high-dose therapy period also contained a ﬁxed effect for study drug
during the initial therapy period (duloxetine/pregabalin).
Table 3
Summary of response rates based on the Brief Pain Inventory Modiﬁed Short Form 24-hour average pain at the end of the initial therapy and the combination/high-dose therapy
periods.
N Number (%) of responders P-value a
P50% reduction in BPI-MSF 24-hour average pain
Initial therapy (Week 8)
Duloxetine (60 mg/day) 375 151 (40.3)
Pregabalin (300 mg/day) 374 104 (27.8)
Comparison duloxetine vs. pregabalin <0.001*
Combination/high-dose therapy (Week 16)
Combination 165 86 (52.1)
Group 2 (60 mg DLX + 300 mg PGB) 74 38 (51.4)
Group 3 (300 mg PGB + 60 mg DLX) 91 48 (52.7)
High-dose monotherapy 163 64 (39.3)
Group 1 (60 mg DLX + 60 mg DLX) 67 19 (28.4)
Group 4 (300 mg PGB + 300 mg PGB) 96 45 (46.9)
Comparison combination vs. high-dose monotherapy 0.068
P30% reduction in BPI-MSF 24-hour average pain
Initial therapy (Week 8)
Duloxetine (60 mg/day) 375 195 (52.0)
Pregabalin (300 mg/day) 374 138 (36.9)
Comparison duloxetine vs. pregabalin <0.001*
Combination/High-dose Therapy (Week 16)
Combination 165 102 (61.8)
Group 2 (60 mg DLX + 300 mg PGB) 74 44 (59.5)
Group 3 (300 mg PGB + 60 mg DLX) 91 58 (63.7)
High-dose monotherapy 163 91 (55.8)
Group 1 (60 mg DLX + 60 mg DLX) 67 32 (47.8)
Group 4 (300 mg PGB + 300 mg PGB) 96 59 (61.5)
Comparison combination vs. high-dose monotherapy 0.565
P2-point reduction in BPI-MSF 24-hour average pain
Initial therapy (Week 8)
Duloxetine (60 mg/day) 375 214 (57.1)
Pregabalin (300 mg/day) 374 171 (45.7)
Comparison duloxetine vs. pregabalin <0.001*
Combination/high-dose therapy (Week 16)
Combination 165 110 (66.7)
Group 2 (60 mg DLX + 300 mg PGB) 74 48 (64.9)
Group 3 (300 mg PGB + 60 mg DLX) 91 62 (68.1)
High-dose monotherapy 163 105 (64.4)
Group 1 (60 mg DLX + 60 mg DLX) 67 39 (58.2)
Group 4 (300 mg PGB + 300 mg PGB) 96 66 (68.8)
Comparison combination vs. high-dose monotherapy 0.843
BPI-MSF, Brief Pain Inventory Modiﬁed Short Form; DLX, duloxetine; N, number of patients with available data; PGB, pregabalin.
a P-values from a Cochran-Mantel-Haenszel test adjusted for site.
* Statistically signiﬁcant.
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during the entire course of this study.
During the initial therapy period, a signiﬁcant difference in fa-
vour of duloxetine was seen in the evaluation of treatment-emer-
gent suicidal thoughts or wishes as measured by BDI-II item 9: 7
duloxetine patients (1.8%) compared to 20 pregabalin patients(5.1%; P = 0.017) reported an increase in the BDI-II item 9 score.
During the combination/high-dose therapy period, respective dif-
ference between combination (n = 6 with increase [3.6%]) and
high-dose monotherapy (n = 5 [2.9%]; P = 0.770) was not signiﬁ-
cant. No clinically relevant ﬁndings were seen in other safety
variables.
Fig. 4. Between-therapy differences in efﬁcacy variables at Week 8 of the initial therapy period (A) and combination/high-dose therapy period (B). Mixed-model repeated-
measures analysis. BPI, Brief Pain Inventory; HADS, Hospital Anxiety and Depression Scale; CGI-I, Clinical Global Impression of Improvement; PGI-I, Patient Global Impression
of Improvement. aStatistically signiﬁcant for all scores. bStatistically signiﬁcant in the combination/high-dose therapy period (P = 0.049). Note: The diamond symbol denotes
the least-squares (LS) mean for the difference between duloxetine and pregabalin in the initial therapy period and combination therapy and high-dose monotherapy in the
combination/high-dose therapy period; the horizontal line denotes the associated 95% conﬁdence interval (CI). ‘‘//’’ indicates that the 95% CI line is cut off due to the limited
space. The LS mean Neuropathic Pain Symptom Inventory (NPSI) total score in the initial therapy period was4.8 (95% CI 7.4 to 2.2; P < 0.001) and for the HADS total score
1.01 (95% CI 1.70 to 0.32; P = 0.004). The LS mean NPSI total score in the combination/high-dose therapy period was 1.9 (95% CI 5.5-1.7; P = 0.289) and for the HADS
total score 0.95 (95% CI 2.00-0.12; P = 0.080).
Table 5
Treatment emergent adverse events occurring in at least 3 patients in any group – combination/high-dose therapy period.
TEAE Number (%) of patients
Combination High-dose monotherapy
Group 2
(60 mg DLX + 300 mg PGB)
(N = 75)
Group 3
(300 mg PGB + 60 mg DLX)
(N = 94)
Total
(N = 169)
Group 1
(60 mg DLX + 60 mg DLX)
(N = 73)
Group 4
(300 mg PGB + 300 mg PGB)
(N = 97)
Total
(N = 170)
Patients with TEAE 21 (28.0) 41 (43.6) 62 (36.7) 20 (27.4) 37 (38.1) 57 (33.5)
Dizziness 2 (2.7) 2 (2.1) 4 (2.4) 4 (5.5) 2 (2.1) 6 (3.5)
Nausea 1 (1.3) 4 (4.3) 5 (3.0) 2 (2.7) 1 (1.0) 3 (1.8)
Pain in extremity 3 (4.0) 2 (2.1) 5 (3.0) 3 (4.1) 0 3 (1.8)
Somnolence 0 2 (2.1) 2 (1.2) 1 (1.4) 5 (5.2) 6 (3.5)
Vomiting 0 4 (4.3) 4 (2.4) 0 1 (1.0) 1 (0.6)
Diarrhea 0 1 (1.1) 1 (0.6) 0 3 (3.1) 3 (1.8)
Headache 0 1 (1.1) 1 (0.6) 3 (4.1) 0 3 (1.8)
Hypoglycemia 0 1 (1.1) 1 (0.6) 0 3 (3.1) 3 (1.8)
Weight increased 1 (1.3) 0 1 (0.6) 0 3 (3.1) 3 (1.8)
TEAE, treatment-emergent adverse event; DLX, duloxetine; PGB, pregabalin; N, total number of patients.
Table 4
Treatment-emergent adverse events – initial therapy period and combination/high-dose therapy period.
TEAE category Number (%) of patients
Initial therapy Combination/high-dose therapy
Combination High-dose monotherapy
Duloxetine
(60 mg/
day)
(N = 401)
Pregabalin
(300 mg/
day)
(N = 403)
Group 2
(60 mg
DLX + 300 mg
PGB)
(N = 75)
Group 3
(300 mg
PGB + 60 mg
DLX)
(N = 94)
Total
(N = 169)
Group 1
(60 mg
DLX + 60 mg
DLX)
(N = 73)
Group 4
(300 mg
PGB + 300 mg
PGB)
(N = 97)
Total
(N = 170)
Patients with TEAE 223 (55.6) 232 (57.6) 21 (28.0) 41 (43.6) 62 (36.7) 20 (27.4) 37 (38.1) 57 (33.5)
Patients with SAE 12 (3.0) 13 (3.2) 3 (4.0) 5 (5.3) 8 (4.7) 3 (4.1) 2 (2.1) 5 (2.9)
Patients with AE leading to
discontinuation
46 (11.5) 50 (12.4) 2 (2.7) 5 (5.3) 7 (4.1) 5 (6.8) 3 (3.1) 8 (4.7)
Patients with AE leading to dose
reduction
31 (7.7) 27 (6.7) 0 (0.0) 1 (1.1) 1 (0.6) 0 (0.0) 4 (4.1) 4 (2.4)
Patients with AE leading to
discontinuation and dose
reduction
12 (3.0) 10 (2.5) 0 (0.0) 1 (1.1) 1 (0.6) 0 (0.0) 1 (1.0) 1 (0.6)
TEAE, treatment-emergent adverse event; N, total number of patients; DLX, duloxetine; PGB, pregabalin; SAE, serious adverse event; AE, adverse event.
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During initial therapy, the mean (SD) last-observation-carried-for-
ward change in HbA1c was 0.209% (1.085%) in the duloxetine
group and 0.016% (0.933%) in the pregabalin group. During com-
bination/high-dose therapy, the last-observation-carried-forward
mean (SD) change in HbA1c was 0.125% (1.033%) in the combina-
tion therapy group and 0.072% (0.795%) in the high-dose mono-
therapy group.
4. Discussion
A major problem in the area of neuropathic pain in diabetes is
the considerable lack of active-controlled studies that also assess
combination treatments at lower doses of each of the combined
drugs [27]. This has been highlighted by recent consensus guide-
lines from international institutions, in particular for the treatment
of diabetic peripheral neuropathic pain [22,31], consequently lead-
ing to the present COMBO-DN study. This ﬁrst multicentre, fully
blinded parallel-group study tried to address an important clinical
question: ‘‘Is it better to increase the dose of the current ﬁrst-line
recommended monotherapy or to combine with another ﬁrst-line
recommended drug early on in patients with insufﬁcient pain re-
lief?’’ In exploratory analyses of initial 8-week therapy uncorrected
for multiple comparisons, the design also allowed for a comparison
between doses of duloxetine and pregabalin that corresponded to
half the maximum doses, that is, 60 mg/day and 300 mg/day. Un-
like previous studies on combination treatment [13,14,17,24], the
strengths of our study include its large size, a parallel-group design
where patients and investigators were blinded to treatment
throughout the entire treatment duration, and the use of standard
doses of duloxetine and pregabalin reﬂecting current clinical
practice.
Although the primary end point of a signiﬁcant difference in the
BPI-MSF 24-hour average pain between combination and high-
dose monotherapy could not be demonstrated after combination/
high-dose therapy, between-therapy differences in all efﬁcacy
measures, although not statistically signiﬁcant, consistently fa-
voured combination therapy. Alternative dosages and treatment
periods may have resulted in different outcomes. However, re-
cently reported data from an observational study also showed that
the majority of patients with painful diabetic polyneuropathy did
not require dosing of pregabalin at the upper end of its dosage
range. For patients on pregabalin monotherapy, the mean (SD) dai-
ly dose was 228 mg (95 mg), and only 10% of these patients took
more than 300 mg/day pregabalin as their last dose (i.e., 450 or
600 mg/day) [29]. Moreover, safety and tolerability were not neg-
atively affected when 60 mg/day duloxetine and 300 mg/day pre-
gabalin were combined, and TEAEs were comparable between
high-dose monotherapy and combination treatment. Thus, the re-
sults of the COMBO-DN study may be more generalizable to rou-
tine clinical care, providing relevant information with regard to a
more realistic clinical approach in patients suffering from diabetic
peripheral neuropathic pain.
The COMBO-DN study adds to the knowledge on combination
therapy based on 2 previous, smaller, randomized, placebo-con-
trolled, crossover studies. In the ﬁrst study involving 57 patients
with painful neuropathy, 35 of whom had diabetic peripheral neu-
ropathic pain, Gilron et al. showed that lower-dose combination
therapy with gabapentin and morphine was signiﬁcantly more
effective than either drug as monotherapy at a higher dose [14].
However, in contrast with our study, combination treatment in
their study was associated with more TEAEs, which might be
attributable to the much higher proportion of each drug in the
combination arm that amounted to about 75% of the respective
doses when given as monotherapy (combination: 34 mg/day mor-
phine plus 1705 mg/day gabapentin; monotherapy: 45 mg/daymorphine or 2207 mg/day gabapentin) [14]. One can speculate that
if in the COMBO-DN study individual doses of duloxetine and pre-
gabalin in the combination group also would have amounted to
75% of the doses when given as monotherapy (ie, 90 mg/day dul-
oxetine plus 450 mg/day pregabalin for combination treatment),
the primary end point may potentially have been met. However,
TEAEs may also have been more frequent [10]. In a second study,
the same group evaluated the combination of nortriptyline with
gabapentin in 40 patients with diabetic peripheral neuropathic
pain and conﬁrmed better efﬁcacy when given together than either
drug given alone [13]. However, as in their previous study and un-
like the COMBO-DN study, maximum tolerated doses of nortripty-
line (50 mg/day) and gabapentin (2180 mg/day) were used for
combination therapy. The authors also conceded the possibility
of partial unmasking of the research nurses, although their study
was designed as double blind [13].
Our study also included a randomized comparison of duloxetine
(60 mg/day) with pregabalin (300 mg/day) for initial pain therapy
over 8 weeks. In exploratory analyses uncorrected for multiple
comparisons, differences between duloxetine and pregabalin were
statistically signiﬁcant in favour of duloxetine for all BPI-MSF
scores, all NPSI scores with the exception of evoked pains, and all
HADS scores. However, this also indicates that a pregabalin dose
that is somewhat higher than 300 mg/day is needed to show equiv-
alent analgesia compared to duloxetine 60 mg/day in patients with
painful diabetic neuropathy. Previous studies have also suggested
that different drugs for painful neuropathy may have differential
effects on the various pain symptoms or combination of symptoms,
suggesting that they may be mediated by different mechanisms
[1]. In an open study, Tanenberg et al. showed that treatment with
60 mg/day duloxetine was at least as good as treatment with
300 mg/day pregabalin in reducing pain associated with diabetic
neuropathy [26]. As a secondary objective, their study included
the comparison of duloxetine with a combination of duloxetine
and gabapentin. The combination arm was efﬁcacious in pain
reduction, similar to treatment with duloxetine monotherapy
and pregabalin monotherapy. However, in contrast to the COM-
BO-DN study, only patients with inadequate pain response to gaba-
pentin (P900 mg/day) were included in this noninferiority study,
but these results do not contradict the ﬁndings of our study.
In the combination/high-dose therapy period, 46.9% of patients
treated with 600 mg/day pregabalin had a pain reduction ofP50%
compared to only 28.4% treated with 120 mg/day duloxetine, indi-
cating that pregabalin was able to catch up at the end of the high-
dose therapy period. This may have resulted from more pregaba-
lin-treated patients entering the combination/high-dose therapy
period due to nonresponse after initial therapy, even though the
better response with 600 mg/day pregabalin than with 120 mg/
day duloxetine is most likely due to the clearer dose response with
pregabalin [21,23]. However, the 2 high-dose groups in the combi-
nation/high-dose therapy period cannot be compared, as the treat-
ment outcome in this second 8-week period is confounded with
the treatments received in the initial therapy period, after which
responders (reduction of P30% in BPI-MSF 24-hour average pain)
discontinued. Thus, it is difﬁcult to draw conclusions for this com-
parison based on the design of the COMBO-DN study. A different
study design that compares ﬂexible dosing of the 2 drugs based
on response and side effects within each patient would be required
to make such a comparison.
4.1. Conclusions
The COMBO-DN study was a large multinational combination
treatment trial in patients with diabetic peripheral neuropathic
pain. Even though the primary end point was not achieved, efﬁcacy
results consistently favoured combination therapy with 60 mg/day
2624 S. Tesfaye et al. / PAIN

154 (2013) 2616–2625duloxetine and 300 mg/day pregabalin, indicating that such a com-
bination therapy might be a reasonable clinical option compared to
increasing the dose for patients not achieving response after initial
8-week monotherapy with 60 mg/day duloxetine or 300 mg/day
pregabalin. This is further supported by the lack of evidence that
a combination of duloxetine with pregabalin at these doses nega-
tively affects safety and tolerability. For initial 8-week treatment
of painful diabetic neuropathy, exploratory analyses suggest better
analgesia of duloxetine compared to pregabalin at half their max-
imum dose. Further studies should be conducted to conﬁrm these
results.
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